Enarodustat (JTZ-951) - 98%, high purity , Egl nine homolog 1 inhibitor, CAS No.1262132-81-9, Egl nine homolog 1 inhibitor

Item Number
E414445
Grouped product items
SKUSizeAvailabilityPrice Qty
E414445-5mg
5mg
In stock
$92.90
E414445-10mg
10mg
In stock
$151.90
E414445-25mg
25mg
In stock
$342.90
E414445-50mg
50mg
In stock
$434.90
E414445-100mg
100mg
In stock
$815.90

HIF Inhibitors

Basic Description

SynonymsC17H16N4O4 | CS-0031647 | Glycine, N-((7-hydroxy-5-(2-phenylethyl)(1,2,4)triazolo(1,5-a)pyridin-8-yl)carbonyl)- | JSK7TUA223 | UNII-JSK7TUA223 | Enarodustat (JTZ-951) | JTZ 951 | HY-109057 | BJ162590 | DB14985 | EX-A4798 | MS-25187 | 2-(7-Hydroxy-5-phenet
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsEnarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionEgl nine homolog 1 inhibitor
Product Description

Information

Enarodustat (JTZ-951) Enarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia.


Targets

PHD2 (Cell-free assay); EPO release from Hep3B cells (Cell-based assay) 0.22 μM; 5.7 μM(EC50)


In vitro

Enarodustat (JTZ-951) inhibits PHD2 with IC50 of 0.22 μM and the EPO release from Hep3B cells with EC50 of 5.7 μM.


In vivo

JTZ-951 (compound 14), with a 5-phenethyl substituent on the triazolopyridine group, increases hemoglobin levels with daily oral dosing in rats. JTZ-951 is rapidly absorbed after oral administration and disappears shortly thereafter, which can be advantageous in terms of safety. JTZ-951 is selected as a clinical candidate.


Cell Research(from reference)

Cell lines:Hep3B cells 

Incubation Time:24 h 

Product Properties

ALogP1.511
HBD Count2
Rotatable Bond6

Associated Targets(Human)

EGLN1 Tclin Egl nine homolog 1 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 2-[[7-oxo-5-(2-phenylethyl)-3H-[1,2,4]triazolo[1,5-a]pyridine-8-carbonyl]amino]acetic acid
INCHI InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24)
InChi Key FJYRBJKWDXVHHO-UHFFFAOYSA-N
Canonical SMILES C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O
Isomeric SMILES C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O
PubChem CID 50899324
Molecular Weight 340.33

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

10 results found

Lot NumberCertificate TypeDateItem
F2307406Certificate of AnalysisMay 09, 2023 E414445
F2307407Certificate of AnalysisMay 09, 2023 E414445
F2307408Certificate of AnalysisMay 09, 2023 E414445
F2307409Certificate of AnalysisMay 09, 2023 E414445
F2307410Certificate of AnalysisMay 09, 2023 E414445
F2307411Certificate of AnalysisMay 09, 2023 E414445
F2307412Certificate of AnalysisMay 09, 2023 E414445
F2307413Certificate of AnalysisMay 09, 2023 E414445
F2307415Certificate of AnalysisMay 09, 2023 E414445
F2307416Certificate of AnalysisMay 09, 2023 E414445

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro DMSO: 68 mg/mL (199.8 mM); Ethanol: 2.5 mg/mL (7.34 mM); Water: Insoluble;
DMSO(mg / mL) Max Solubility68
DMSO(mM) Max Solubility199.806070578556
Water(mg / mL) Max Solubility<1

Related Documents

References

1. Sanford M, McCormack PL.  (2017)  Erratum Regarding "Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD" (Am J Kidney Dis. 2017;69[6]:815-826)..  Am J Kidney Dis,  69  (6): (869).  [PMID:28532635] [10.1021/op500134e]
2. Markham A.  (2021)  Enarodustat: First Approval..  Drugs,  81  (1): (169-174).  [PMID:33320297] [10.1021/op500134e]
3. Ogoshi Y, Matsui T, Mitani I, Yokota M, Terashita M, Motoda D, Ueyama K, Hotta T, Ito T, Hase Y et al..  (2017)  Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia..  ACS Med Chem Lett,  (12): (1320-1325).  [PMID:29259755] [10.1021/op500134e]
4. Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M.  (2019)  JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor..  Eur J Pharmacol,  859  (13): (172532).  [PMID:31301309] [10.1021/op500134e]

Solution Calculators